BACKGROUND: In childhood, the most common reason for a neurogenic bladder is related to spinal dysraphism, mostly myelodysplasia. AIMS: Herein, we present the EAU/ESPU guidelines in respect to the diagnostics, timetable for investigations and conservative management including clean intermittent catheterization (CIC). MATERIAL AND METHODS: After a systematic literature review covering the period 2000 to 2017, the ESPU/EUAU guideline for neurogenic bladder underwent an update. RESULTS: The EAU/ESPU guideline panel advocates a proactive approach. In newborns with spina bifida, CIC should be started as soon as possible after birth. In those with intrauterine closure of the defect, urodynamic studies are recommended be performed before the patient leaves the hospital. In those with closure after birth urodynamics should be done within the next 3 months. Anticholinergic medication (oxybutynin is the only well-investigated drug in this age group-dosage 0.2-0.4 mg/kg weight per day) should be applied, if the urodynamic study confirmed detrusor overactivity. Close follow-up including ultrasound, bladder diary, urinalysis, and urodynamics are necessary within the first 6 years and after that the time intervals can be prolonged, depending on the individual risk and clinical course. In all other children with the suspicion of a neurogenic bladder due to various reasons as tethered cord, inflammation, tumors, trauma, or other reasons as well as those with anorectal malformations, urodynamics-preferable video-urodynamics, should be carried out as soon as there is a suspicion of a neurogenic bladder and conservative treatment should be started soon after confirmation of the diagnosis of neurogenic bladder. With conservative treatment the upper urinary tract is preserved in up to 90%, urinary tract infections are common, but not severe, complications of CIC are quite rare and continence can be achieved at adolescence in up to 80% without further treatment. DISCUSSION AND CONCLUSIONS: The transition into adulthood is a complicated time for both patients, their caregivers and doctors, as the patient wants to become independent from caregivers and treatment compliance is reduced. Also, transition to adult clinics for patients with neurogenic bladders is often not well-established.

Department of Pediatric Adolescent and Reconstructive Urology Medical Faculty Mannheim University Medical Center Mannheim Heidelberg University Mannheim Germany

Department of Urology 1st Faculty of Medicine in Praha General Teaching Hospital Charles University Prague Czech Republic

Department of Urology Aarhus University Hospital Aarhus Denmark

Department of Urology and Pediatric Urology University Medical Centre Groningen Rijks Universiteit Groningen Groningen The Netherlands

Department of Urology Erasmus University Medical Center Rotterdam The Netherlands

Department of Urology Medical University of Innsbruck Austria

Department of Urology University of Leuven Belgium

Division of Pediatric Urology Department of Urology Hacettepe University Ankara Turkey

Division of Pediatric Urology Department of Urology Istanbul Medeniyet University Istanbul Turkey

Zobrazit více v PubMed

Torre M, Buffa P, Jasonni V, Cama A. Long-term urologic outcome in patients with caudal regression syndrome, compared with meningomyelocele and spinal cord lipoma. J Pediatr Surg. 2008;43(3):530-533.

Maerzheuser S, Jenetzky E, Zwink N, et al. German network for congenital uro-rectal malformations: first evaluation and interpretation of postoperative urological complications in anorectal malformations. Pediatr Surg Int. 2011;27(10):1085-1089.

Hinman F, Baumann FW. Vesical and ureteral damage from voiding dysfunction in boys without neurologic or obstructive disease. J Urol. 2017;197(2 suppl):S127-S131.

Ochoa B. Can a congenital dysfunctional bladder be diagnosed from a smile? The Ochoa syndrome updated. Pediatr Nephrol. 2004;19(1):6-12.

Bauer SB. Neurogenic bladder: etiology and assessment. Pediatr Nephrol. 2008;23(4):541-551.

Tarcan T, Bauer S, Olmedo E, Khoshbin S, Kelly M, Darbey M. Long-term followup of newborns with myelodysplasia and normal urodynamic findings: is followup necessary? J Urol. 2001;165(2):564-567.

McGuire EJ, Woodside JR, Borden TA. Upper urinary tract deterioration in patients with myelodysplasia and detrusor hypertonia: a followup study. J Urol. 1983;129(4):823-826.

Hopps CV, Kropp KA. Preservation of renal function in children with myelomeningocele managed with basic newborn evaluation and close followup. J Urol. 2003;169(1):305-308.

Bauer S. Clean intermittent catheterization of infants with myelodysplasia - the argument for early asssessment and treatment of infants with spina bifida. Dialog Ped Urol. 2000;23(11):2-3.

Sillen U, Hansson E, Hermansson G, Hjalmas K, Jacobsson B, Jodal U. Development of the urodynamic pattern in infants with myelomeningocele. Br J Urol. 1996;78(4):596-601.

Dogan HS, Stein R, 't Hoen LA, et al. Are EAU/ESPU pediatric urology guideline recommendations on neurogenic bladder well received by the patients? Results of a survey on awareness in spina bifida patients and caregivers. Neurourol Urodyn. 2019;38:1625-1631.

Veenboer PW, Bosch JL, van Asbeck FW, de Kort LM. Upper and lower urinary tract outcomes in adult myelomeningocele patients: a systematic review. PLOS One. 2012;7(10):e48399.

Lloyd JC, Nseyo U, Madden-Fuentes RJ, Ross SS, Wiener JS, Routh JC. Reviewing definitions of urinary continence in the contemporary spina bifida literature: a call for clarity. J Pediatr Urol. 2013;9(5):567-574.

Drzewiecki BA, Bauer SB. Urodynamic testing in children: indications, technique, interpretation and significance. J Urol. 2011;186(4):1190-1197.

Bauer SB, Hallett M, Khoshbin S, et al. Predictive value of urodynamic evaluation in newborns with myelodysplasia. JAMA. 1984;252(5):650-652.

Madersbacher H. The various types of neurogenic bladder dysfunction: an update of current therapeutic concepts. Paraplegia. 1990;28(4):217-229.

Fox JA, Dudley AG, Bates C, Cannon GM. Cystatin C as a marker of early renal insufficiency in children with congenital neuropathic bladder. J Urol. 2014;191(5 suppl):1602-1607.

Dangle PP, Ayyash O, Kang A, et al. Cystatin C-calculated glomerular filtration rate-a marker of early renal dysfunction in patients with neuropathic bladder. Urology. 2017;100:213-217.

Fernbach SK, Maizels M, Conway JJ. Ultrasound grading of hydronephrosis: introduction to the system used by the Society for Fetal Urology. Pediatr Radiol. 1993;23(6):478-480.

Kim WJ, Shiroyanagi Y, Yamazaki Y. Can bladder wall thickness predict videourodynamic findings in children with spina bifida? J Urol. 2015;194:180-183.

Bauer SB, Austin PF, Rawashdeh YF, et al. International Children's Continence Society's recommendations for initial diagnostic evaluation and follow-up in congenital neuropathic bladder and bowel dysfunction in children. Neurourol Urodyn. 2012;31(5):610-614.

Almodhen F, Capolicchio JP, Jednak R, El Sherbiny M. Postpubertal urodynamic and upper urinary tract changes in children with conservatively treated myelomeningocele. J Urol. 2007;178(4):1479-1482.

Bauer SB, Nijman RJM, Drzewiecki BA, Sillen U, Hoebeke P. International Children's Continence Society standardization report on urodynamic studies of the lower urinary tract in children. Neurourol Urodyn. 2015;34(7):640-647.

Zermann DH, Lindner H, Huschke T, Schubert J. Diagnostic value of natural fill cystometry in neurogenic bladder in children. Eur Urol. 1997;32(2):223-228.

Jorgensen B, Olsen LH, Jorgensen TM. Natural fill urodynamics and conventional cystometrogram in infants with neurogenic bladder. J Urol. 2009;181(4):1862-1868.

Leonardo CR, Filgueiras MF, Vasconcelos MM, et al. Risk factors for renal scarring in children and adolescents with lower urinary tract dysfunction. Pediatr Nephrol. 2007;22(11):1891-1896.

Shiroyanagi Y, Suzuki M, Matsuno D, Yamazaki Y. The significance of 99mtechnetium dimercapto-succinic acid renal scan in children with spina bifida during long-term followup. J Urol. 2009;181(5):2262-2266.

Veenboer PW, Hobbelink MG, Ruud Bosch JL, et al. Diagnostic accuracy of Tc-99m DMSA scintigraphy and renal ultrasonography for detecting renal scarring and relative function in patients with spinal dysraphism. Neurourol Urodyn. 2015;34(6):513-518.

Wide P, Mattsson GG, Mattsson S. Renal preservation in children with neurogenic bladder-sphincter dysfunction followed in a national program. J Pediatr Urol. 2012;8(2):187-193.

Stein R, Assion C, Beetz R, et al. Diagnostik und Therapie der neurogenen Blasenfunktionsstörungen bei Patienten mit Meningomyelocele Leitlinie AWMF Register 043/047 Klasse: S2k; 2013.

Routh JC, Cheng EY, Austin JC, et al. Design and methodological considerations of the centers for disease control and prevention urologic and renal protocol for the newborn and young child with spina bifida. J Urol. 2016;196(6):1728-1734.

Snow-Lisy DC, Yerkes EB, Cheng EY. Update on urological management of spina bifida from prenatal diagnosis to adulthood. J Urol. 2015;194(2):288-296.

Lee B, Featherstone N, Nagappan P, McCarthy L, O'Toole S. British Association of Paediatric Urologists consensus statement on the management of the neuropathic bladder. J Pediatr Urol. 2016;12(2):76-87.

Kessler TM, Lackner J, Kiss G, Rehder P, Madersbacher H. Early proactive management improves upper urinary tract function and reduces the need for surgery in patients with myelomeningocele. Neurourol Urodyn. 2006;25(7):758-762.

Jorgensen B, Olsen LH, Jorgensen TM. Long-term follow-up in spinal dysraphism: outcome of renal function and urinary and faecal continence. Scand J Urol Nephrol. 2010;44(2):95-100.

Araujo Júnior E, Tonni G, Martins WP. Outcomes of infants followed-up at least 12 months after fetal open and endoscopic surgery for meningomyelocele: a systematic review and meta-analysis. J Evid Based Med. 2016;9:125-135.

Horst M, Mazzone L, Schraner T, et al. Prenatal myelomeningocele repair: do bladders better? Neurourol Urodyn. 2017;36:1651-1658.

Leal Da Cruz M, Liguori R, Garrone G, et al. Categorization of bladder dynamics and treatment after fetal myelomeningocele repair: first 50 cases prospectively assessed. J Urol. 2015;193(5):1808-1811.

Carr MC. Urological results after fetal myelomeningocele repair in pre-MOMS trial patients at the children's hospital of Philadelphia. Fetal Diagn Ther. 2015;37(3):211-218.

Danzer E, Thomas NH, Thomas A, et al. Long-term neurofunctional outcome, executive functioning, and behavioral adaptive skills following fetal myelomeningocele surgery. Am J Obstet Gynecol. 2016;214(2):269.e1-269.e8.

Macedo A, Leal M, Rondon A, Ortiz V, Moron AF, Cavalheiro S. Urological evaluation of patients that had undergone in utero myelomeningocele closure: a prospective assessment at first presentation and early follow-up. Do their bladder benefit from it? Neurourol Urodyn. 2015;34(5):461-464.

Rendeli C, Nucera E, Ausili E, et al. Latex sensitisation and allergy in children with myelomeningocele. Childs Nerv Syst. 2006;22:28-32.

Kaefer M, Pabby A, Kelly M, Darbey M, Bauer SB. Improved bladder function after prophylactic treatment of the high risk neurogenic bladder in newborns with myelomentingocele. J Urol. 1999;162(3 Pt 2):1068-1071.

Park JM. Early reduction of mechanical load of the bladder improves compliance: experimental and clinical observations. Dialogues in Pediatric. Urology. 2000;23:6-7.

Dik P, Klijn AJ, van Gool JD, de Jong-de Vos van Steenwijk CC, de Jong TP. Early start to therapy preserves kidney function in spina bifida patients. Eur Urol. 2006;49(5):908-913.

Moore KN, Fader M, Getliffe K. Long-term bladder management by intermittent catheterisation in adults and children. Cochrane Database Syst Rev. 2007;(4):1-46. CD006008.

Kiddoo D, Sawatzky B, Bascu CD, Dharamsi N, Afshar K, Moore KN. Randomized crossover trial of single use hydrophilic coated vs multiple use polyvinylchloride catheters for intermittent catheterization to determine incidence of urinary tract infection. J Urol. 2015;194:174-179.

Prieto J, Murphy CL, Moore KN, Fader M. Intermittent catheterisation for long-term bladder management. Cochrane Database Syst Rev. 2014;(9):1-9. CD006008.

Lindehall B, Abrahamsson K, Jodal U, Olsson I, Sillen U. Complications of clean intermittent catheterization in young females with myelomeningocele: 10 to 19 years of followup. J Urol. 2007;178(3 Pt 1):1053-1055.

Lucas EJ, Baxter C, Singh C, et al. Comparison of the microbiological milieu of patients randomized to either hydrophilic or conventional PVC catheters for clean intermittent catheterization. J Pediatr Urol. 2016;12(3):172.e1-172.e8.

Andersson KE, Chapple CR, Cardozo L, et al. Pharmacological treatment of overactive bladder: report from the International Consultation on Incontinence. Curr Opin Urol. 2009;19(4):380-394.

Rawashdeh YF, Austin P, Siggaard C, et al. International Children's Continence Society's recommendations for therapeutic intervention in congenital neuropathic bladder and bowel dysfunction in children. Neurourol Urodyn. 2012;31(5):615-620.

Wu HY, Baskin LS, Kogan BA. Neurogenic bladder dysfunction due to myelomeningocele: neonatal versus childhood treatment. J Urol. 1997;157(6):2295-2297.

Abrams P, Andersson KE, Buccafusco JJ, et al. Muscarinic receptors: their distribution and function in body systems, and the implications for treating overactive bladder. Br J Pharmacol. 2006;148(5):565-578.

Goessl C, Knispel HH, Fiedler U, Harle B, Steffen-Wilke K, Miller K. Urodynamic effects of oral oxybutynin chloride in children with myelomeningocele and detrusor hyperreflexia. Urology. 1998;51(1):94-98.

Lee JH, Kim KR, Lee YS, et al. Efficacy, tolerability, and safety of oxybutynin chloride in pediatric neurogenic bladder with spinal dysraphism: a retrospective, multicenter, observational study. Korean J Urol. 2014;55(12):828-833.

Krause P, Fuhr U, Schnitker J, Albrecht U, Stein R, Rubenwolf P. Pharmacokinetics of intravesical versus oral oxybutynin in healthy adults: results of an open label, randomized, prospective clinical study. J Urol. 2013;190(5):1791-1797.

Van Meel TD, De Wachter S, Wyndaele JJ. The effect of intravesical oxybutynin on the ice water test and on electrical perception thresholds in patients with neurogenic detrusor overactivity. Neurourol Urodyn. 2010;29(3):391-394.

Humblet M, Verpoorten C, Christiaens MH, et al. Long-term outcome of intravesical oxybutynin in children with detrusor-sphincter dyssynergia: with special reference to age-dependent parameters. Neurourol Urodyn. 2015;34(4):336-342.

Guerra LA, Moher D, Sampson M, Barrowman N, Pike J, Leonard M. Intravesical oxybutynin for children with poorly compliant neurogenic bladder: a systematic review. J Urol. 2008;180(3):1091-1097.

Haferkamp A, Staehler G, Gerner HJ, Dorsam J. Dosage escalation of intravesical oxybutynin in the treatment of neurogenic bladder patients. Spinal Cord. 2000;38(4):250-254.

Gish P, Mosholder AD, Truffa M, Johann-Liang R. Spectrum of central anticholinergic adverse effects associated with oxybutynin: comparison of pediatric and adult cases. J Pediatr. 2009;155(3):432-434.

Todorova A, Vonderheid-Guth B, Dimpfel W. Effects of tolterodine, trospium chloride, and oxybutynin on the central nervous system. J Clin Pharmacol. 2001;41(6):636-644.

Giramonti KM, Kogan BA, Halpern LF. The effects of anticholinergic drugs on attention span and short-term memory skills in children. Neurourol Urodyn. 2008;27(4):315-318.

Veenboer PW, Huisman J, Chrzan RJ, et al. Behavioral effects of long-term antimuscarinic use in patients with spinal dysraphism: a case control study. J Urol. 2013;190(6):2228-2232.

Reddy PP, Borgstein NG, Nijman RJM, Ellsworth PI. Long-term efficacy and safety of tolterodine in children with neurogenic detrusor overactivity. J Pediatr Urol. 2008;4(6):428-433.

Mahanta K, Medhi B, Kaur B, Narasimhan KL. Comparative efficacy and safety of extended-release and instant-release tolterodine in children with neural tube defects having cystometric abnormalities. J Pediatr Urol. 2008;4(2):118-123.

Bolduc S, Moore K, Lebel S, Lamontagne P, Hamel M. Double anticholinergic therapy for refractory overactive bladder. J Urol. 2009;182(4 suppl):2033-2038.

Bolduc S, Moore K, Nadeau G, Lebel S, Lamontagne P, Hamel M. Prospective open label study of solifenacin for overactive bladder in children. J Urol. 2010;184(4 suppl):1668-1673.

Christoph F, Moschkowitsch A, Kempkensteffen C, Schostak M, Miller K, Schrader M. Long-term efficacy of tolterodine and patient compliance in pediatric patients with neurogenic detrusor overactivity. Urol Int. 2007;79(1):55-59.

Nadeau G, Schröder A, Moore K, et al. Double anticholinergic therapy for refractory neurogenic and nonneurogenic detrusor overactivity in children: Long-term results of a prospective open-label study. Can Urol Assoc J. 2014;8(5-6):175-180.

Schulte-Baukloh H, Mürtz G, Heine G, et al. Urodynamic effects of propiverine in children and adolescents with neurogenic bladder: results of a prospective long-term study. J Pediatr Urol. 2012;8(4):386-392.

Wollner J, Pannek J. Initial experience with the treatment of neurogenic detrusor overactivity with a new beta-3 agonist (mirabegron) in patients with spinal cord injury. Spinal Cord. 2016;54(1):78-82.

Austin PF, Homsy YL, Masel JL, Cain MP, Casale AJ, Rink RC. alpha-Adrenergic blockade in children with neuropathic and nonneuropathic voiding dysfunction. J Urol. 1999;162(3 Pt 2):1064-1067.

Homsy Y, Arnold P, Zhang W. Phase IIb/III dose ranging study of tamsulosin as treatment for children with neuropathic bladder. J Urol. 2011;186(5):2033-2039.

Ausili E, Focarelli B, Tabacco F, et al. Transanal irrigation in myelomeningocele children: an alternative, safe and valid approach for neurogenic constipation. Spinal Cord. 2010;48(7):560-565.

Malone PS, Ransley PG, Kiely EM. Preliminary report: the antegrade continence enema. Lancet. 1990;336(8725):1217-1218.

Anselmo CB, do Amaral RD, Oliveira DE, et al. Left-colon antegrade enema (LACE): long-term experience with the Macedo-Malone approach. Neurourol Urodyn. 2017;36(1):111-115.

Zegers BS, Winkler-Seinstra PL, Uiterwaal CS, de Jong TV, Kimpen JL, de Jong-de Vos van Steenwijk CC. Urinary tract infections in children with spina bifida: an inventory of 41 European centers. Pediatr Nephrol. 2009;24(4):783-788.

Hansson S, Jodal U, Noren L, Bjure J. Untreated bacteriuria in asymptomatic girls with renal scarring. Pediatrics. 1989;84(6):964-968.

Hansson S, Caugant D, Jodal U, Svanborg-Eden C. Untreated asymptomatic bacteriuria in girls: I-stability of urinary isolates. BMJ. 1989;298(6677):853-855.

Hansson S, Jodal U, Lincoln K, Svanborg-Eden C. Untreated asymptomatic bacteriuria in girls: II-effect of phenoxymethylpenicillin and erythromycin given for intercurrent infections. BMJ. 1989;298(6677):856-859.

Zegers SH, Dieleman J, van der Bruggen T, Kimpen J, de Jong-de Vos van Steenwijk C. The influence of antibiotic prophylaxis on bacterial resistance in urinary tract infections in children with spina bifida. BMC Infect Dis. 2017;17(1):63.

Akil I, Ozen C, Cengiz B. Do patients with neurogenic bladder treated with clean intermittent catheterization need antibacterial prophylaxis? Turk J Med Sci. 2016;46(4):1151-1154.

Mutlu H, Ekinci Z. Urinary tract infection prophylaxis in children with neurogenic bladder with cranberry capsules: randomized controlled trial. ISRN Pediatr. 2012;2012:317280.

Johnson HW, Anderson JD, Chambers GK, Arnold WJ, Irwin BJ, Brinton JR. A short-term study of nitrofurantoin prophylaxis in children managed with clean intermittent catheterization. Pediatrics. 1994;93(5):752-755.

Schlager TA, Anderson S, Trudell J, Hendley JO. Nitrofurantoin prophylaxis for bacteriuria and urinary tract infection in children with neurogenic bladder on intermittent catheterization. J Pediatr. 1998;132(4):704-708.

Misseri R, Rosenbaum DH, Rink RC. Reflux in cystoplasties. Arch Esp Urol. 2008;61(2):213-217.

Helmy TE, Hafez AT. Vesicouretral reflux with neuropathic bladder: studying the resolution rate after ileocystoplasty. Urology. 2013;82(2):425-429.

Polackwich AS, Skoog SJ, Austin JC. Long-term followup after endoscopic treatment of vesicoureteral reflux with dextranomer/hyaluronic acid copolymer in patients with neurogenic bladder. J Urol. 2012;188(4 suppl):1511-1515.

Engel JD, Palmer LS, Cheng EY, Kaplan WE. Surgical versus endoscopic correction of vesicoureteral reflux in children with neurogenic bladder dysfunction. J Urol. 1997;157(6):2291-2294.

Roth JD, Misseri R, Cain MP, Szymanski KM. Mobility, hydrocephalus and quality of erections in men with spina bifida. J Pediatr Urol. 2017;13(3):264.e1-264.e6.

Verhoef M, Barf HA, Vroege JA, et al. Sex education, relationships, and sexuality in young adults with spina bifida. Arch Phys Med Rehabil. 2005;86(5):979-987.

Elias ER, Sadeghi-Nejad A. Precocious puberty in girls with myelodysplasia. Pediatrics. 1994;93(3):521-522.

Trollmann R, Strehl E, Dorr HG. Precocious puberty in children with myelomeningocele: treatment with gonadotropin-releasing hormone analogues. Dev Med Child Neurol. 1998;40(1):38-43.

Senousy SM, Farag MK, Gouda AS, El Noury MA, Dabbous OA, Gaber KR. Association between biomarkers of vitamin B12 status and the risk of neural tube defects. J Obstet Gynaecol Res. 2018;44(10):1902-1908.

Viswanathan M, Treiman KA, Kish-Doto J, Middleton JC, Coker-Schwimmer EJ, Nicholson WK. Folic acid supplementation for the prevention of neural tube defects: an updated evidence report and systematic review for the US preventive services task force. JAMA. 2017;317(2):190-203.

Committee on Practice Bulletins-Obstetrics Trinidad MC, Wick M. Practice Bulletin No.187: neural tube defects. Obstet Gynecol. 2017;130(6):e279-e290.

Cardenas DD, Topolski TD, White CJ, McLaughlin JF, Walker WO. Sexual functioning in adolescents and young adults with spina bifida. Arch Phys Med Rehabil. 2008;89(1):31-35.

Gatti C, Del Rossi C, Ferrari A, Casolari E, Casadio G, Scire G. Predictors of successful sexual partnering of adults with spina bifida. J Urol. 2009;182(4 suppl):1911-1916.

Lassmann J, Garibay Gonzalez F, Melchionni JB, Pasquariello PS Jr, Snyder HM Jr. Sexual function in adult patients with spina bifida and its impact on quality of life. J Urol. 2007;178(4 Pt 2):1611-1614.

Palmer JS, Kaplan WE, Firlit CF. Erectile dysfunction in patients with spina bifida is a treatable condition. J Urol. 2000;164(3 Pt 2):958-961.

Bong GW, Rovner ES. Sexual health in adult men with spina bifida. ScientificWorldJournal. 2007;7:1466-1469.

Overgoor ML, de Jong TP, Cohen-Kettenis PT, Edens MA, Kon M. Increased sexual health after restored genital sensation in male patients with spina bifida or a spinal cord injury: the TOMAX procedure. J Urol. 2013;189(2):626-632.

Visconti D, Noia G, Triarico S, et al. Sexuality, pre-conception counseling and urological management of pregnancy for young women with spina bifida. Eur J Obstet Gynaecol Reprod Biol. 2012;163(2):129-133.

Radmayr C, Bogaert G, Dogan HS, et al. EAU/ESPU Paediatric Urology Guidelines, https://uroweb.org/guideline/paediatric-urology/: EAU; 2019.